ELV · NYSE · STOCK
Elevance Health (ELV) Stock Analysis
$412.51
52W $274.84 – $436.24
56/100
$89.50B
18.3
0.71
Is ELV Bullish or Bearish?
Mixed.
Innellis AI committee rates Elevance Health (ELV) Watch with a composite score of 56/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +3.68 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -16.32 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Technical Analyst sees a compelling case — price structure making higher highs and higher lows. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- News sentiment is positive (+0.33 across 24 articles, 14d) — News
Bear Case
- EPS declining -4.2% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Current ratio of 0.19 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
56/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 57%
of 192 Healthcare peers
Value Analyst
neutral
58
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
Growth Analyst
neutral
44
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− EPS declining -4.2% YoY despite any revenue growth
Technical Analyst
bullish
68
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.19 is tight -- limited short-term liquidity cushion
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 24 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 54.8 to 56.3.
- Bullish support removed: 2 signal(s) disappeared.
- New bullish signals: 2 appeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Technical Analyst: score 61->68 (+7); +1 bullish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
67.7
Neutral
MACD Histogram
1.086
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Mixed
Support
$412.14
Resistance
$415.43
Bollinger %B
0.74
Inside Bands
Price vs Moving Averages
EMA 9
$400.43
Above
EMA 21
$400.26
Above
EMA 50
$398.96
Above
EMA 200
$378.26
Above
Fundamental Analysis
Valuation
93
Growth
59
Profitability
43
Financial Health
95
Cash Flow
70
Valuation
P/E Ratio
18.3×
P/B Ratio
2.00×
PEG Ratio
-4.08
Dividend Yield
1.66%
52W High
$436.24
52W Low
$274.84
Quality & Growth
ROE
1290.3%
ROA
466.0%
Gross Margin
3895.2%
Operating Margin
351.1%
Revenue Growth YoY
—
Debt / Equity
0.69
AI Fundamental Assessment
P/E ratio of 18.3 (inexpensive relative to a 15-40x range); Price-to-book of 2.0x; PEG ratio of -4.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 12.9%; Return on assets of 4.7%; Net margin of 2.5%; Gross margin of 39.0%; Current ratio of 2.05 (healthy short-term liquidity); Debt-to-equity of 0.69; Free cash flow per share is positive (28.86); Most recent quarter beat estimates by 18.9%; 4 consecutive earnings beats; EPS growth decelerating (+277.8% -> -40.8% QoQ); Average YoY EPS growth of -15.7%; Analyst estimates rising over recent quarters
Get the Full ELV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →